AprilBio Co Ltd
KOSDAQ:397030
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11 070
25 000
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AprilBio Co Ltd
Total Equity
AprilBio Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
AprilBio Co Ltd
KOSDAQ:397030
|
Total Equity
â‚©57.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celltrion Inc
KRX:068270
|
Total Equity
â‚©17T
|
CAGR 3-Years
67%
|
CAGR 5-Years
45%
|
CAGR 10-Years
31%
|
||
SK Bioscience Co Ltd
KRX:302440
|
Total Equity
â‚©1.7T
|
CAGR 3-Years
86%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Total Equity
â‚©817.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Equity
â‚©480.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Equity
â‚©177.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
AprilBio Co Ltd
Glance View
AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.
See Also
What is AprilBio Co Ltd's Total Equity?
Total Equity
57.7B
KRW
Based on the financial report for Dec 31, 2023, AprilBio Co Ltd's Total Equity amounts to 57.7B KRW.
What is AprilBio Co Ltd's Total Equity growth rate?
Total Equity CAGR 1Y
-17%
Over the last year, the Total Equity growth was -17%.